Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Risk and Volatility Prime Medicine has a
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Earnings and Valuation This table compares Athira
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations. Earnings and Valuation This table compares Athira
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Valuation and Earnings This table compares Prime
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares Athira Pharma and
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year
DNB Asset Management AS purchased a new stake in Prime Medicine, Inc. (NYSE: PRME) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 182,133 shares of the company's stock, valued at approximately $1,009,000. DNB Asset Management AS owned 0.14% of Prime
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago.
